Study on autonomic neuropathy of the digestive system caused by bortezomib in the treatment of multiple myeloma

References

• Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: A review. JAMA. 2022 Feb 1;327(5):464–477.
   PubMed Web of Science ®Google Scholar
• Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci (Basel). 2021 Jan;9(1):3.
   PubMedGoogle Scholar
• Terpos E, Katodritou E, de la Rubia J, et al. Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practice. Eur J Haematol. 2018 Oct;101(4):556–565.
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Egashira N. Pathological mechanisms of bortezomib-induced peripheral neuropathy. Int J Mol Sci. 2021 Jan;22(2):888.
   PubMed Web of Science ®Google Scholar
• Goel L, Gupta P, Pahuja M. Mechanistic involvement of inflammation in bortezomib-induced peripheral neuropathy. Comb Chem High Throughput Screen. 2022;25(10):1595–1600.
   PubMed Web of Science ®Google Scholar
• Mele G, Coppi MR, Melpignano A, et al. Paralytic ileus following “subcutaneous bortezomib” therapy: focus on the clinical emergency-report of two cases. Clin Exp Med. 2016 Feb;16(1):99–101.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International myeloma working group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328–e346.
   PubMed Web of Science ®Google Scholar
• Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr (Engl Ed). 2021 Jan;112(1):90–92.
   PubMed Web of Science ®Google Scholar
• Gressin R, Daguindau N, Tempescul A, et al. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. Haematologica. 2019;104(1):138–146.
   PubMed Web of Science ®Google Scholar
• Keating M, Dasanu CA. Strategy to reduce bortezomib-induced paralytic ileus in patients with myeloma and impaired renal function. BMJ Case Rep. 2016: bcr2016217000.
   PubMedGoogle Scholar
• Ramsenthaler C, Kane P, Gao W, et al. Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis. Eur J Haematol. 2016;97:416–429.
   PubMed Web of Science ®Google Scholar
• Tathineni P, Cancarevic I, Malik BH. Uncommon presentations of multiple myeloma. Cureus. 2020 Jun;12(6):e8400.
   PubMed Web of Science ®Google Scholar
• Mishra SB, Azim A, Mukherjee A. Multiple myeloma presenting as acute pancreatitis. Am J Emerg Med. 2017;35:1385–1381.
   Web of Science ®Google Scholar
• Kadowaki S, Yamaguchi K. Chemotherapy-induced stomatitis and diarrhea. Gan To Kagaku Ryoho. 2011;38(11):1761–1766.
   PubMedGoogle Scholar
• Tan CRC, Abdul-Majeed S, Cael B, et al. Clinical pharmacokinetics and pharmacodynamics of bortezomib. Clin Pharmacokinet. 2019 Feb;58(2):157–168.
   PubMed Web of Science ®Google Scholar
• Jamieson D, Lee J, Cresti N, et al. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. Cancer Chemother Pharmacol. 2014 Oct;74(4):667–674.
   PubMed Web of Science ®Google Scholar
• Perfetti V, Palladini G, Brunetti L, et al. Bortezomib-induced paralytic ileus is a potential gastrointestinal side effect of this first-in-class anticancer proteasome inhibitor. Eur J Gastroenterol Hepatol. 2007;19(7):599–601.
   PubMed Web of Science ®Google Scholar
• Koda Y, Mori T, Shimizu T, et al. Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients. Rinsho Ketsueki. 2012;53(8):760–764.
   PubMedGoogle Scholar
• Fukushima T, Iwao H, Sakai T, et al. Once-weekly bortezomib plus dexamethasone therapy induced complete response, reducing severe gastrointestinal adverse events for a patient with relapsed multiple myeloma-a case report. Gan To Kagaku Ryoho. 2012;39(5):805–807.
   PubMedGoogle Scholar
• Fukushima T, Nakamura T, Iwao H, et al. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. Anticancer Res. 2011;31(6):2297–2302.
   PubMed Web of Science ®Google Scholar
• Zhang QL, Liu YZ, Lin DQ, et al. Clinical analysis of 26 cases of multiple myeloma with intestinal obstruction treated with bortezomib. Zhonghua Xue Ye Xue Za Zhi. 2017;38(07):625–627.
   PubMedGoogle Scholar
• Hassan Zafar MS, Khan AA, Aggarwal S, et al. Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma. South Asian J Cancer. 2018 Jan–Mar;7(1):58–60.
   PubMed Web of Science ®Google Scholar
• Scott K, Hayden PJ, Will A, et al. Bortezomib for the treatment of multiple myeloma. Cochrane Database Syst Rev. 2016 Apr;4:CD010816.
   PubMedGoogle Scholar
• Lee SE, Choi K, Han S, et al. Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. Anticancer Drugs. 2017;28(6):660–668.
   PubMed Web of Science ®Google Scholar
• Marathe CS, Jones KL, Wu T, et al. Gastrointestinal autonomic neuropathy in diabetes. Auton Neurosci. 2020 Dec;229:102718.
   PubMed Web of Science ®Google Scholar
• Kuźnik E, Dudkowiak R, Adamiec R, et al. Diabetic autonomic neuropathy of the gastrointestinal tract. Prz Gastroenterol. 2020;15(2):89–93.
   PubMed Web of Science ®Google Scholar
• Du YT, Rayner CK, Jones KL, et al. Gastrointestinal symptoms in diabetes: prevalence, assessment, pathogenesis, and management. Diabetes Care. 2018 Mar;41(3):627–637.
   PubMed Web of Science ®Google Scholar
• Qamar N, Castano D, Patt C, et al. Meta-analysis of alcohol induced gut dysbiosis and the resulting behavioral impact. Behav Brain Res. 2019 Dec;376:112196.
   PubMed Web of Science ®Google Scholar